Ashim Kumar Sen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ashim Kumar Sen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Dhanya B. Sen
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
13 shared publications - Rajesh A. Maheshwari
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
6 shared publications - Dillip Kumar Dash
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
4 shared publications - Dipti Gohil
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
3 shared publications - Ramachandran Balaraman
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara – 391760, Gujarat
3 shared publications - Shaileshkumar K. Koradia
Krishna School of Pharmacy & Research, Krishna Edu Campus, Drs. Kiran & Pallavi Patel Global University (KPGU), Varnama, Vadodara, India
3 shared publications
Latest Publications
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-21
Ethnobotanical, Phyto-pharmacological, and Bio-economic Prospects of Phyllostachys edulis (Carrière) J.Houz.: Review of Recent Advances
Background: Phyllostachys edulis (Carrière) J.Houz. (Moso bamboo) has historically been recognised as a structural timber resource ("Green Gold"), overshadowing its significant potential as a reservoir of therapeutic bioactive compounds. This review aims to thoroughly integrate current knowledge on phytochemistry, pharmacological mechanisms of action, safety issues, and agricultural and industrial aspects to identify future research areas. Methods: The literature search was conducted across five major databases (PubMed, ScienceDirect, Google Scholar, ResearchGate, and Semantic Scholar) covering the period from January 2019 to December 2025. Following rigorous screening of 630 initial records, 101 primary studies that met strict inclusion criteria for phytochemical characterisation and molecular pharmacology were synthesised. Important articles published before 2019 were included to provide essential background and context. Results: Phytochemical analysis reveals a unique radial metabolite gradient, dominated by stable flavone C-glycosides (isoorientin, vitexin) and immunomodulatory polysaccharides (BSDF-1). Mechanistic evidence supports their efficacy in regulating metabolic syndrome via the PI3K/Akt signalling axis and in mitigating chronic inflammation by suppressing the NLRP3 inflammasome. Additionally, novel sterol derivatives isolated from shoot residues exhibit significant cytotoxicity against the MCF-7 breast cancer cell line. Discussion: Clinical translation is currently impeded by the poor oral bioavailability of Cglycosides and the species' capacity for heavy metal bioaccumulation (Pb, Cd) in polluted soils. Conclusion: P. edulis represents a validated therapeutic bioresource with distinct advantages in metabolic and neuroprotective interventions. Future utilisation must prioritise the development of nano-delivery systems to overcome bioavailability barriers, the implementation of rigorous heavy metal monitoring to ensure safety within a circular bioeconomy, and well-designed clinical studies, pharmacokinetic optimisation, standardisation of bioactive constituents, and advanced drugdelivery strategies to facilitate clinical translation.
- 14 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Food, Nutrition & Agriculture
- Vol. 17, 1-21
Ethnobotanical, Phyto-pharmacological, and Bio-economic Prospects of Phyllostachys edulis (Carrière) J.Houz.: Review of Recent Advances
Background: Phyllostachys edulis (Carrière) J.Houz. (Moso bamboo) has historically been recognised as a structural timber resource ("Green Gold"), overshadowing its significant potential as a reservoir of therapeutic bioactive compounds. This review aims to thoroughly integrate current knowledge on phytochemistry, pharmacological mechanisms of action, safety issues, and agricultural and industrial aspects to identify future research areas. Methods: The literature search was conducted across five major databases (PubMed, ScienceDirect, Google Scholar, ResearchGate, and Semantic Scholar) covering the period from January 2019 to December 2025. Following rigorous screening of 630 initial records, 101 primary studies that met strict inclusion criteria for phytochemical characterisation and molecular pharmacology were synthesised. Important articles published before 2019 were included to provide essential background and context. Results: Phytochemical analysis reveals a unique radial metabolite gradient, dominated by stable flavone C-glycosides (isoorientin, vitexin) and immunomodulatory polysaccharides (BSDF-1). Mechanistic evidence supports their efficacy in regulating metabolic syndrome via the PI3K/Akt signalling axis and in mitigating chronic inflammation by suppressing the NLRP3 inflammasome. Additionally, novel sterol derivatives isolated from shoot residues exhibit significant cytotoxicity against the MCF-7 breast cancer cell line. Discussion: Clinical translation is currently impeded by the poor oral bioavailability of Cglycosides and the species' capacity for heavy metal bioaccumulation (Pb, Cd) in polluted soils. Conclusion: P. edulis represents a validated therapeutic bioresource with distinct advantages in metabolic and neuroprotective interventions. Future utilisation must prioritise the development of nano-delivery systems to overcome bioavailability barriers, the implementation of rigorous heavy metal monitoring to ensure safety within a circular bioeconomy, and well-designed clinical studies, pharmacokinetic optimisation, standardisation of bioactive constituents, and advanced drugdelivery strategies to facilitate clinical translation.
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- Open Access
- 6 June 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (3) , 979-983
Advancements in Sample Preparation Techniques for Quantitative Pharmaceutical Detection in Biological Samples
Researchers have recently shifted their attention to the bio-analysis of pharmaceuticals as a result of the growing demand for medication development and the growing worry about the presence of pharmaceuticals in the environment. The very low quantities of medicines in biological samples and the complicated structure of sample matrices provide substantial obstacles, nevertheless. As a result, a lot of work has gone into finding solutions to these problems, mostly by improving methods of sample preparation. High throughput, automated, on-site, non-invasive, and in vivo analysis focusing sample preparation techniques is a major growing trend. This trend has substantial implications for both biomedical and environmental analyses. This review explores recent progress in sample preparation techniques over the past decade for the quantitative bio-analysis of pharmaceuticals. The discussion includes an overview and summary of these advances, along with a comparative analysis of the merits associated with each sample preparation technique. Additionally, the review addresses innovative approaches such as electro membrane extraction and micro fluidic devices. Furthermore, the focus extends to future prospects, emphasizing sample preparation techniques with the potential for in vivo pharmaceutical analysis. The discussion of future trends highlights aspects such as miniaturization, high specificity, and portability, underscoring the ongoing evolution of sample preparation methodologies in the field of pharmaceutical analysis.
- 6 June 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (3) , 979-983
Open AccessAdvancements in Sample Preparation Techniques for Quantitative Pharmaceutical Detection in Biological Samples
Researchers have recently shifted their attention to the bio-analysis of pharmaceuticals as a result of the growing demand for medication development and the growing worry about the presence of pharmaceuticals in the environment. The very low quantities of medicines in biological samples and the complicated structure of sample matrices provide substantial obstacles, nevertheless. As a result, a lot of work has gone into finding solutions to these problems, mostly by improving methods of sample preparation. High throughput, automated, on-site, non-invasive, and in vivo analysis focusing sample preparation techniques is a major growing trend. This trend has substantial implications for both biomedical and environmental analyses. This review explores recent progress in sample preparation techniques over the past decade for the quantitative bio-analysis of pharmaceuticals. The discussion includes an overview and summary of these advances, along with a comparative analysis of the merits associated with each sample preparation technique. Additionally, the review addresses innovative approaches such as electro membrane extraction and micro fluidic devices. Furthermore, the focus extends to future prospects, emphasizing sample preparation techniques with the potential for in vivo pharmaceutical analysis. The discussion of future trends highlights aspects such as miniaturization, high specificity, and portability, underscoring the ongoing evolution of sample preparation methodologies in the field of pharmaceutical analysis.
- Open Access
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Exploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Open AccessExploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- 21 February 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (2)
A Stability Indicating HPLC Methodology Applying Quality by Design for the Concurrent Estimation of Luliconazole and Clobetasol Propionate in Cream Formulation
Antifungal agents containing azole ring (luliconazole [LULI]) and corticosteroid (clobetasol propionate [CLOB]) combination shows great therapeutic effects on skin infections by eliminating the fungus that is responsible for the infection and reducing the inflammation of the skin. The research work intended to create a liquid chromatographic methodology with stability study for estimating LULI and CLOB applying design of experiment approach. LULI and CLOB were analyzed utilizing a Hypersil BDS C 18 column (250 × 4.6 mm, 5 µm), using elution solvent comprising 0.1 M sodium phosphate buffer (pH 6.0) combined with methanol in a ratio of 40:60 v/v. The proposed method a flow rate of 1 mL/min and a detection wavelength of 240 nm. A 3 2 full factorial design was utilized to optimize the mobile phase. The methodology had undergone validation using ICH strategies. The study on force degradation was conducted for the cream formulation containing both the drugs. The satisfactory linearity range for LULI was found to be 10–30 µg/mL, whereas 0.5–1.5 µg/mL for CLOB. The method demonstrated good sensitivity, with detection limit and quantification limit of 0.255 and 0.774 µg/mL for LULI along with 0.106 and 0.322 µg/mL for CLOB. The established methodology was found to be precise (%RSD < 2) and accurate (recovery between 98% and 102%). The degradation studies aimed to confirm the efficient separation of LULI and CLOB from their degradation products. From the degradation chromatograms it has been demonstrated that any degradation products, if present, do not interfere with the active constituents.
- 21 February 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (2)
A Stability Indicating HPLC Methodology Applying Quality by Design for the Concurrent Estimation of Luliconazole and Clobetasol Propionate in Cream Formulation
Antifungal agents containing azole ring (luliconazole [LULI]) and corticosteroid (clobetasol propionate [CLOB]) combination shows great therapeutic effects on skin infections by eliminating the fungus that is responsible for the infection and reducing the inflammation of the skin. The research work intended to create a liquid chromatographic methodology with stability study for estimating LULI and CLOB applying design of experiment approach. LULI and CLOB were analyzed utilizing a Hypersil BDS C 18 column (250 × 4.6 mm, 5 µm), using elution solvent comprising 0.1 M sodium phosphate buffer (pH 6.0) combined with methanol in a ratio of 40:60 v/v. The proposed method a flow rate of 1 mL/min and a detection wavelength of 240 nm. A 3 2 full factorial design was utilized to optimize the mobile phase. The methodology had undergone validation using ICH strategies. The study on force degradation was conducted for the cream formulation containing both the drugs. The satisfactory linearity range for LULI was found to be 10–30 µg/mL, whereas 0.5–1.5 µg/mL for CLOB. The method demonstrated good sensitivity, with detection limit and quantification limit of 0.255 and 0.774 µg/mL for LULI along with 0.106 and 0.322 µg/mL for CLOB. The established methodology was found to be precise (%RSD < 2) and accurate (recovery between 98% and 102%). The degradation studies aimed to confirm the efficient separation of LULI and CLOB from their degradation products. From the degradation chromatograms it has been demonstrated that any degradation products, if present, do not interfere with the active constituents.
- 23 January 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Concurrent Analysis of Racecadotril, Ofloxacin, and Ornidazole in a Fixed‐Dose Combination by RP‐HPLC–DAD Method
The pharmaceutical combination of Racecadotril (RAC), Ofloxacin (OFL), and Ornidazole (ORN) is a commonly prescribed treatment for diarrhea and dysentery in pediatric patients. A rapid and highly sensitive reverse phase–high‐performance liquid chromatography–diode array detector (RP‐HPLC–DAD) method has been established for the concurrent analysis of all three drugs in a combined oral suspension. Drugs were separated by chromatography using a Sapphire octadecylsilane (ODS) C18 (150 × 4.6 mm, 5 µm) column, operated at 30°C. The elution solvent consisted of a mixture of acetonitrile and 0.1% triethylamine solution (70:30 v/v), with the pH adjusted to 3.1 using 10% orthophosphoric acid. The flow rate was maintained at 1 mL/min, and all three drugs were monitored at 230 nm. The method showed linearity within the ranges: RAC (3–9 µg/mL), OFL (10–30 µg/mL), and ORN (25–75 µg/mL). Retention times were 2.03 min for OFL, 2.99 min for ORN, and 6.99 min for RAC. The drug content for RAC, OFL, and ORN ranged from 100.92% to 101.39%, 98.55% to 100.76%, and 99.33% to 101.22%, respectively, with recoveries of 96.33%–102.16%, 97.50%–101.32%, and 98.25%–100.76%, and %RSD values consistently below 2 in within‐day, between‐day, and repeatability studies, demonstrating method precision. The projected chromatography technique has been authenticated in line with International Council on Harmonization Q2 (R1) guidelines. This approach offers a short runtime of 10 min, providing an economically efficient chromatographic technique for the concomitant assessment of RAC, OFL, and ORN in a combined oral suspension preparation.
- 23 January 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Concurrent Analysis of Racecadotril, Ofloxacin, and Ornidazole in a Fixed‐Dose Combination by RP‐HPLC–DAD Method
The pharmaceutical combination of Racecadotril (RAC), Ofloxacin (OFL), and Ornidazole (ORN) is a commonly prescribed treatment for diarrhea and dysentery in pediatric patients. A rapid and highly sensitive reverse phase–high‐performance liquid chromatography–diode array detector (RP‐HPLC–DAD) method has been established for the concurrent analysis of all three drugs in a combined oral suspension. Drugs were separated by chromatography using a Sapphire octadecylsilane (ODS) C18 (150 × 4.6 mm, 5 µm) column, operated at 30°C. The elution solvent consisted of a mixture of acetonitrile and 0.1% triethylamine solution (70:30 v/v), with the pH adjusted to 3.1 using 10% orthophosphoric acid. The flow rate was maintained at 1 mL/min, and all three drugs were monitored at 230 nm. The method showed linearity within the ranges: RAC (3–9 µg/mL), OFL (10–30 µg/mL), and ORN (25–75 µg/mL). Retention times were 2.03 min for OFL, 2.99 min for ORN, and 6.99 min for RAC. The drug content for RAC, OFL, and ORN ranged from 100.92% to 101.39%, 98.55% to 100.76%, and 99.33% to 101.22%, respectively, with recoveries of 96.33%–102.16%, 97.50%–101.32%, and 98.25%–100.76%, and %RSD values consistently below 2 in within‐day, between‐day, and repeatability studies, demonstrating method precision. The projected chromatography technique has been authenticated in line with International Council on Harmonization Q2 (R1) guidelines. This approach offers a short runtime of 10 min, providing an economically efficient chromatographic technique for the concomitant assessment of RAC, OFL, and ORN in a combined oral suspension preparation.
- Top Cited PapersOpen Access
- 3 January 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-16
Analytical quality by design (AQbD) methodology for concurrent determination of perindopril erbumine and moxonidine hydrochloride using RP-HPLC with an eco-friendly evaluation
- 3 January 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-16
Top Cited PapersOpen AccessAnalytical quality by design (AQbD) methodology for concurrent determination of perindopril erbumine and moxonidine hydrochloride using RP-HPLC with an eco-friendly evaluation
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- 10 May 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (7)
Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
A combination of fixed dose tablet containing 0.5 mg lobeglitazone sulfate (LBZ) and 1 mg glimepiride (GLM) has demonstrated efficacy in enhancing glycemic control in diabetes. The projected work aimed to develop and validate a high‐performance thin‐layer chromatographic (HPTLC) methodology for the precise quantification of both the drugs in tablet formulations. The HPTLC analysis utilized aluminium plates layered with silica gel 60F 254 , and the solvent system consisted of ethyl acetate, benzene, and hexane (4:3:1 v/v/v) followed by densitometric scanning at 238 nm. The R f value was found to be 0.68 ± 0.001 for LBZ and 0.48 ± 0.002 for GLM. The methodology exhibited linearity in the range of 100–2000 ng/band for LBZ and 200–4000 ng/band for GLM, with correlation coefficients of 0.9988 and 0.9981, respectively. Exceptional sensitivity was observed, with detection limits of 23.86 ng/band for LBZ and 58.26 ng/band for GLM, along with quantification limits of 72.32 ng/band for LBZ and 176.55 ng/band for GLM. The method demonstrated precision (% relative standard deviation of peak area < 2) and accuracy (recovery between 97% and 102%). The suggested method is suitable for quantifying both the drugs in tablets, making it useful for routine quality control in laboratories.
- 10 May 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (7)
Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
A combination of fixed dose tablet containing 0.5 mg lobeglitazone sulfate (LBZ) and 1 mg glimepiride (GLM) has demonstrated efficacy in enhancing glycemic control in diabetes. The projected work aimed to develop and validate a high‐performance thin‐layer chromatographic (HPTLC) methodology for the precise quantification of both the drugs in tablet formulations. The HPTLC analysis utilized aluminium plates layered with silica gel 60F 254 , and the solvent system consisted of ethyl acetate, benzene, and hexane (4:3:1 v/v/v) followed by densitometric scanning at 238 nm. The R f value was found to be 0.68 ± 0.001 for LBZ and 0.48 ± 0.002 for GLM. The methodology exhibited linearity in the range of 100–2000 ng/band for LBZ and 200–4000 ng/band for GLM, with correlation coefficients of 0.9988 and 0.9981, respectively. Exceptional sensitivity was observed, with detection limits of 23.86 ng/band for LBZ and 58.26 ng/band for GLM, along with quantification limits of 72.32 ng/band for LBZ and 176.55 ng/band for GLM. The method demonstrated precision (% relative standard deviation of peak area < 2) and accuracy (recovery between 97% and 102%). The suggested method is suitable for quantifying both the drugs in tablets, making it useful for routine quality control in laboratories.
- 13 December 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (3)
Analytical quality by design‐based thin‐layer chromatography method development and validation for assay and content uniformity testing of the anti‐neoplastic drug Axitinib in tablet formulation
The current study aims to develop and validate an analytical quality by design approach‐based high‐performance thin‐layer chromatographic (HPTLC) method for the analysis of Axitinib tablet samples. The chromatographic conditions in the TLC method were optimized using a three‐level full factorial design. The mobile phase composition and chamber saturation time served as the independent variables for optimization. The mobile phase used for TLC separation on pre‐coated aluminum plates with silica gel 60 F254 consisted of a mixture of ethyl acetate and isopropyl alcohol in a ratio of 9:1 (v/v). Axitinib was quantified at 330 nm using the densitometric method. Axitinib peak from tablet formulation was verified against the reference standard by comparing its single band at R f 0.44 ± 0.02. Linearity was found to exist between 100 and 600 ng/band, with a correlation coefficient (r 2 ) of 0.9978. The percentage recovery was obtained as 98.21%–99.05%. The system was validated by determining the parameters according to the guidelines of the International Council for Harmonization of Technical Conditions for Medical Products for Human Use. The proposed TLC method can be effectively applied to routine quality control of a pharmaceutical product.
- 13 December 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (3)
Analytical quality by design‐based thin‐layer chromatography method development and validation for assay and content uniformity testing of the anti‐neoplastic drug Axitinib in tablet formulation
The current study aims to develop and validate an analytical quality by design approach‐based high‐performance thin‐layer chromatographic (HPTLC) method for the analysis of Axitinib tablet samples. The chromatographic conditions in the TLC method were optimized using a three‐level full factorial design. The mobile phase composition and chamber saturation time served as the independent variables for optimization. The mobile phase used for TLC separation on pre‐coated aluminum plates with silica gel 60 F254 consisted of a mixture of ethyl acetate and isopropyl alcohol in a ratio of 9:1 (v/v). Axitinib was quantified at 330 nm using the densitometric method. Axitinib peak from tablet formulation was verified against the reference standard by comparing its single band at R f 0.44 ± 0.02. Linearity was found to exist between 100 and 600 ng/band, with a correlation coefficient (r 2 ) of 0.9978. The percentage recovery was obtained as 98.21%–99.05%. The system was validated by determining the parameters according to the guidelines of the International Council for Harmonization of Technical Conditions for Medical Products for Human Use. The proposed TLC method can be effectively applied to routine quality control of a pharmaceutical product.